The Heart Institute, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH.
Ionis Pharmaceuticals, Inc, Carlsbad, CA.
Blood Adv. 2023 Apr 25;7(8):1404-1417. doi: 10.1182/bloodadvances.2022007586.
Previous studies suggested that contact pathway factors drive thrombosis in mechanical circulation. We used a rabbit model of veno-arterial extracorporeal circulation (VA-ECMO) to evaluate the role of factors XI and XII in ECMO-associated thrombosis and organ damage. Factors XI and XII (FXI, FXII) were depleted using established antisense oligonucleotides before placement on a blood-primed VA-ECMO circuit. Decreasing FXII or FXI to < 5% of baseline activity significantly prolonged ECMO circuit lifespan, limited the development of coagulopathy, and prevented fibrinogen consumption. Histological analysis suggested that FXII depletion mitigated interstitial pulmonary edema and hemorrhage whereas heparin and FXI depletion did not. Neither FXI nor FXII depletion was associated with significant hemorrhage in other organs. In vitro analysis showed that membrane oxygenator fibers (MOFs) alone are capable of driving significant thrombin generation in a FXII- and FXI-dependent manner. MOFs also augment thrombin generation triggered by low (1 pM) or high (5 pM) tissue factor concentrations. However, only FXI elimination completely prevented the increase in thrombin generation driven by MOFs, suggesting MOFs augment thrombin-mediated FXI activation. Together, these results suggest that therapies targeting FXII or FXI limit thromboembolic complications associated with ECMO. Further studies are needed to determine the contexts wherein targeting FXI and FXII, either alone or in combination, would be most beneficial in ECMO. Moreover, studies are also needed to determine the potential mechanisms coupling FXII to end-organ damage in ECMO.
先前的研究表明,接触途径因素在机械循环中引发血栓形成。我们使用兔静脉-动脉体外循环(VA-ECMO)模型来评估因子 XI 和 XII 在 ECMO 相关血栓形成和器官损伤中的作用。在将血液预充 VA-ECMO 回路之前,使用已建立的反义寡核苷酸来耗竭因子 XI 和 XII(FXI、FXII)。将 FXII 或 FXI 降低至基线活性的 < 5% 显著延长 ECMO 回路寿命,限制了凝血功能障碍的发展,并防止了纤维蛋白原的消耗。组织学分析表明,FXII 耗竭减轻了间质肺水肿和出血,而肝素和 FXI 耗竭则没有。FXI 或 FXII 耗竭均与其他器官的明显出血无关。体外分析表明,膜式氧合纤维(MOFs)本身就能够以 FXII 和 FXI 依赖性的方式驱动显著的凝血酶生成。MOFs 还增强了低(1 pM)或高(5 pM)组织因子浓度触发的凝血酶生成。然而,只有 FXI 消除完全阻止了 MOFs 驱动的凝血酶生成的增加,这表明 MOFs 增强了凝血酶介导的 FXI 激活。总之,这些结果表明,靶向 FXII 或 FXI 的疗法可限制 ECMO 相关的血栓栓塞并发症。需要进一步的研究来确定单独或联合靶向 FXI 和 FXII 在 ECMO 中最有益的情况。此外,还需要研究来确定 FXII 与 ECMO 中终末器官损伤相关的潜在机制。